New targeted treatment for newly diagnosed CBF-AML with KIT mutation
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new targeted therapy for a specific type of leukemia (CBF-AML with a KIT gene change) in people who have not yet had treatment. The goal is to see if adding a KIT inhibitor to standard chemotherapy can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a specific type of leukemia called CBF-AML that also has a change in the KIT gene
- You have not yet received chemotherapy or other treatment for this leukemia (except possibly very low-dose hydroxyurea or cytarabine)
- You are either between 18 and 64 and in good general health, OR you are 65 or older, or 18–64 with some health problems like heart or kidney issues
- Your liver, kidneys, and heart function are good enough for the study (your doctor will check this)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a pill called avapritinib to keep leukemia from coming back after a stem cell transplant. It is for people with AML that has a KIT mutation.
This study tests whether using a genetic profile of your leukemia plus a very sensitive test for leftover cancer cells can guide a more personalized treatment plan. The goal is to give you the most effective therapy while avoiding unnecessary side effects.
This trial tests a targeted drug called avapritinib in children and teens with a specific type of leukemia (CBF-AML) that has a KIT gene change and has come back or not responded to treatment. The goal is to see if avapritinib is safe and effective for these patients.
This trial tests a combination of three drugs (avapritinib, azacitidine, and venetoclax) for people whose acute myeloid leukemia (AML) has returned after a stem cell transplant. It targets a specific genetic change (C-KIT mutation) to try to stop the cancer from growing.
This Phase 2 trial studies avapritinib, a targeted medicine, for people whose cancer has specific KIT or PDGFRA genetic changes. It may help shrink or slow growth of certain advanced cancers, including some brain tumors, when standard treatments have not worked or for specific glioblastoma cases.
This trial studies avapritinib, a targeted medicine, for people with advanced or returning gastrointestinal stromal tumors (GIST) whose tumor does not have PDGFRA exon 18 mutations. It aims to see how well the drug can shrink tumors or control the disease.
Hear when a new Acute Myeloid Leukemia With T(8;21)(Q22;Q22) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.